Vascular Biogenics Ltd was incorporated on January 27, 2000 as a company limited by shares under the name Medicard Ltd. It is a clinical-stage bio-pharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. Its clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body's natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms, an oncology program and an anti-inflammatory program. Its product candidate from its oncology program, VB-111, is a gene-based biologic that is initially developing for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. The Company has obtained fast track designation for VB-111 in the United States for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. It has 134 granted patents for its oncology program and 86 granted patents for its anti-inflammatory program. Its registered trademarks in several countries include the following: 'Vts,' 'Vascular Targeting Systems,' 'Vbl,' 'Vascular Biogenics' And 'Vascular Therapeutics'.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.